Visceral leishmaniasis (also known as kala-azar) is characterized by fever, weight loss, swelling of the spleen and liver, and pancytopenia. If it is not treated, the fatality rate in developing countries can be as high as 100% within 2 years. In a high risk situation for perioperative bleeding due to severe thrombocytopenia/coagulopathy, we present a rare challenge for urgent splenectomy in a patient with previously undiagnosed visceral leishmaniasis. A histologic examination of the spleen revealed a visceral leishmaniasis, and the patient was successfully treated with amphotericin B.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875283 | PMC |
| http://dx.doi.org/10.3390/medicina58020184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Baseline infection prevalence, risk factors and treatment outcomes of visceral leishmaniasis in Northeastern Uganda: A cross-sectional study.
PLoS Negl Trop Dis
January 2025
Department of Public Health, Faculty of Health Sciences, Mbale Campus, Busitema University, Mbale City, Uganda.
Introduction: Visceral leishmaniasis (VL) also known as Kala-azar is one of the neglected tropical diseases (NTD) of public health importance. Despite being a disease of a long history, the condition remains poorly studied especially in East Africa. For instance, whereas, the geographical location of the disease is known, there is a stark paucity of data on the burden, risk factors and clinical outcomes of this contribution in Northeastern Uganda.
View Article and Find Full Text PDFCutaneous Leishmaniasis Masquerading as Diabetic Foot: A Call for Vigilance.
Acta Dermatovenerol Croat
November 2024
Khalid Al Aboud King Faisal Hospital P.O Box 5440, Makkah, Saudi Arabia;
parts of the world (1,2). CL is characterized by significant clinical variability. An ulcerated nodule on the exposed parts of the body (corresponding to the parasite inoculation site by the vector insect) is the classic presentation.
View Article and Find Full Text PDFConcomitant HIV-associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation.
Br J Haematol
January 2025
Hematology Laboratory, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.
Ritonavir enhances the efficacy of amprenavir: A promising combination therapy by targeting Leishmania DNA topoisomerase I for treatment of visceral leishmaniasis.
Exp Parasitol
January 2025
Department of Biotechnology, Savitribai Phule Pune University, 411007, Pune, India. Electronic address:
Visceral leishmaniasis (VL) is an opportunistic infection in HIV patients with higher relapse and mortality rate. The number of HIV-VL patients is comparatively higher in areas where both infections are endemic. However, the conventional chemotherapeutic agents have limited success due to drug toxicity, efficacy variance and overall cost of treatment.
View Article and Find Full Text PDFSerosurvey of Visceral Leishmaniasis in Organ Transplant Recipients in the South of Iran.
Transplant Proc
January 2025
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Background: Visceral leishmaniasis (VL) can become active and cause specific problems in transplant recipients. The current study was conducted with the aim of serological evaluation of VL in transplant patients in a comprehensive transplantation center in Fars province southern Iran.
Methods: The study population included 150 organ transplant recipients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!